On February 18, 2025, Alvotech and Teva announced the FDA acceptance of an aBLA for AVT06 (aflibercept), a proposed biosimilar of Regeneron’s EYLEA^® (aflibercept).  This aBLA joins Celltrion’s CT-P42 (aflibercept) awaiting FDA-approval.  Alvotech and Teva are also developing AVT29 as a biosimilar to Regeneron’s EYLEA^® HD (aflibercept), a higher dose (8 mg) version of EYLEA^® (2 mg).  The FDA has already approved five aflibercept biosimilars, including Biocon / Mylan’s Yesafili™ (aflibercept-jbvf), Samsung Bioepis’s Opuviz™ (aflibercept-yszy), Formycon’s Ahzantive^® (aflibercept-mrbb), Sandoz’s Enzeevu™ (aflibercept-abzv), and Amgen’s Pavblu™ (aflibercept-ayyh).

In November 2024, Amgen launched Pavblu™ at-risk as the first EYLEA^® biosimilar in the U.S. (previously reported Amgen Launches Pavblu™ as the First EYLEA^® Biosimilar in the U.S.).  Numerous other EYLEA^® biosimilars have had their launches delayed by preliminary injunctions, including Opuviz™, Ahzantive^®, and CT-P42 (previously reported Preliminary Injunctions Issued Preventing Launch of EYLEA^® Biosimilars).  Yesafili™ has been permanently enjoined from launching prior to the expiration of Regeneron’s U.S. Patent No. 11,084,865 (previously reported Permanent Injunction Issued Preventing Launch of EYLEA^® Biosimilar Yesafili™).

There are currently eight ongoing litigations and related appeals for EYLEA^® biosimilars.  There have not been any patent disputes related to AVT06 to date.

Regeneron reported EYLEA^® U.S. sales of $4.767 billion in FY2024.

For more information about these and other biosimilar patent disputes, please visit BiologicsHQ.

 

_____________________________________________________

The author would like to thank April Breyer Menon for her contributions to this article.